Clarivate Epidemiology’s coverage of CKD comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the total prevalence of CKD for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 10 years for the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) and the other countries covered in this report. In addition to forecasting the total prevalent patient population, we estimate the number of drug-treatment opportunities in the mature markets.
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
Clarivate Epidemiology’s CKD forecast will answer the following questions:
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following CKD patient populations:
Note: Coverage may vary by country and region.